Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.54 |
| ▸ | PPARG | P37231 | 6/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 8/20 | 0.49 |
| ▸ | CTSS | P25774 | 7/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3935572 | 1.00 | PPARA (0.54) | PPARAPPARGACEPPARDIDO1 | |
| SCHEMBL625897 | 0.90 | PPARA (0.48) | PPARAPPARGACEPPARDIDO1 | |
| SCHEMBL625898 | 0.90 | PPARA (0.48) | PPARAPPARGACEPPARDIDO1 | |
| SCHEMBL1305832 | 0.89 | KLK5 (0.50) | PPARAPPARGACEPPARDCTSK | |
| SCHEMBL12112869 | 0.89 | KLK5 (0.50) | PPARAPPARGACEPPARDCTSK | |
| SCHEMBL31407563 | 0.88 | PPARA (0.53) | PPARAPPARGACEPPARDIDO1 | |
| SCHEMBL625889 | 0.87 | PPARA (0.47) | PPARAPPARGACEPPARDIDO1 | |
| SCHEMBL625890 | 0.87 | PPARA (0.47) | PPARAPPARGACEPPARDIDO1 | |
| SCHEMBL1306620 | 0.84 | PPARA (0.43) | PPARAPPARGACEPPARDIDO1 | |
| SCHEMBL7464162 | 0.83 | PPARA (0.49) | PPARAPPARGACEPPARDIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203918-A1 | METHOD FOR PRODUCING ENANTIOMERIC FORM OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-7514578-B2 | Method for producing enantiomeric form of 2,3-diaminopropionic acid derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20070238778-A1 | METHOD FOR PRODUCING ENANTIOMERIC FORM OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203918-A1 | METHOD FOR PRODUCING ENANTIOMERIC FORM OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES | DDC, ADM2, MTHFD2 | PPARA 1474/4885PPARG 2870/4885ACE 441/4885 |
| US-20070238778-A1 | METHOD FOR PRODUCING ENANTIOMERIC FORM OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES | DDC, DAO, ADM2 | PPARA 1220/4885PPARG 2825/4885ACE 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.